

PCR-/NAT *Helicobacter pylori*
(RV 533) November 2012



Tabelle 1: Probenzusammensetzung und erwartetes Ergebnis.
Sample composition and expected results.

	<i>Erwartet / expected</i>		<i>Probenzusammensetzung / Sample composition</i>
1225331	∅	62	<i>Helicobacter mustelae</i> (~ 1x10 ⁵ CFU/mL)
1225332	++	61/71	<i>Helicobacter pylori</i> (~ 1x10 ⁵ CFU/mL) Clarithromycin resistant (GGA & GTA mut. in 23S rDNA)
1225333	++	61/72	<i>Helicobacter pylori</i> (~ 1x10 ⁵ CFU/mL) Clarithromycin susceptible (wildtype 23S rDNA sequence)
1225334	∅	62	<i>Escherichia coli</i> K12

Tabelle 2: Häufigkeit der Mitteilung verschiedener Befunde.
Absolute numbers of reported individual results.

<i>n = 41</i>	<i>Probennummer (Sample no.)</i>				<i>Inhibition</i>				
	1225331	1225332	1225333	1225334	1225331	1225332	1225333	1225334	
Befund <i>Result</i>									
Positiv	7	41 ¹⁾	40 ¹⁾	0	n.d.	0	0	0	0
Negativ	34	0	1	41	nein <i>no</i>	41	41	41	41
Fraglich <i>Questionable</i>	0	0	0	0	ja <i>yes</i>	0	0	0	0

Tabelle 3: Häufigkeit richtig positiver und richtig negativer NAT-Befunde bei Anwendern verschiedener Methoden.

Absolute numbers and relative frequency of reported true positive and true negative results among various NAT methods.

NAT-Methode [Code] (total number *)	NAT richtig positiv <i>True positive results</i>			NAT richtig negativ <i>True negative results</i>		
	Absolut <i>Absolute</i>	Relativ <i>Relative</i>	%	Absolut <i>Absolute</i>	Relativ <i>Relative</i>	%
Ingenetix ClariRes [26] (n = 3)	6	6 / 6	100	6	6 / 6	100
Commercial assay [27] (n = 14)	27	27 / 28	96	25	25 / 28	89
In house PCR assay [28] (n = 24)	48	48 / 48	100	45	45 / 48	94
Andere / k.A. / other [29] (n = 2)	4	4 / 4	100	3	3 / 4	75

* Durch Mehrfachnennung oder fehlende Angabe kann die absolute Zahl der Ergebnisse (Tab. 2) von der Anzahl der Teilnehmer abweichen.
Due to reporting results of multiple assay systems or missing specifications, the effective numbers are not correlating with the number of participants.

Comments: ¹⁾ Twenty nine of the 41 participants reported results for molecular Clarithromycin-susceptibility testing. With the exception of 1 laboratory, all reported results were correct.